[feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Betallu , MA and Bhalara, SR and Sapnar, BK and Tadke, VB and Meena, K and Srivastava, A and Kundu, GC and Gorain, M (2023) Hybrid Inorganic Complexes as Cancer Therapeutic Agents: In-vitro Validation. Nanotheranostics , 7 (3). pp. 270-280.

Full text not available from this repository. (Request a copy)


A series of novel mixed transition metal-Magnesium tartarate complexes of general formulation [MMg(C4H4O6)2.xH2O] (where M = Mn, Fe, Co, Ni, Cu and Zn) is prepared with bidentate tartarate ligand. The synthesized complexes (C1 to C6) are characterized by various analytical techniques such as Elemental analysis, Thermo gravimetric analysis, FT-IR Spectroscopy, X-ray Diffraction, Magnetic susceptibility study etc. All complexes exhibit the composition MMgL2 where M = Mn(II), Fe(II), Co(II), Ni(II), Cu(II) and Zn(II) and L = bidentate tartarate ligand. Analytical data reveals all complexes possesses 1:1 (metal: ligand) ratio. FT-IR spectral study shows that bidentate tartarate ligand coordinate with metal ion in a bidentate manner through two oxygen atoms. Thermo gravimetric analysis of all complexes shows that degradation curves of complexes agrees with recommended formulae of the complexes. X-ray diffraction technique suggests that all complexes (C1 to C6) are polycrystalline in nature. All newly synthesized metal tartarate complexes and ligand were screened in vitro for their anticancer activity against human breast cancer (MDA-MB-231) cell line. The bioassays of all these complexes showed C3 (Co) and C5 (Cu) Mg-tartarate complexes contains maximum antiproliferative activity at 200 µg/ml concentration on MDA-MB-231 cells as compared to other complexes. MDA-MB-231 cells treated with C3 (Co) and C5 (Cu) Mg-tartarate complexes also showed inhibition in cell migration.

Item Type: Article
Subjects: Cancer Biology
Depositing User: Mr. Rameshwar Nema
Date Deposited: 21 Mar 2023 09:30
Last Modified: 21 Mar 2023 09:30
URI: http://nccs.sciencecentral.in/id/eprint/1250

Actions (login required)

View Item View Item